Think

AMAG Pharmaceuticals Uncertain on Future

Posted by Nick Buenaventura on Jan 18, 2017 11:47:24 AM

AMAG Pharmaceuticals (NASDAQ:AMAG) saw a sharp drop in its debt in the past week following the release of its actual results in sales. Although the pharma company saw its sales rise to a new record in this past year, investors are concerned as its top-selling drug, Makena, is set to lose its patent exclusivity in 2018. The maternal drug aid currently makes up 70% of AMAG's sales and with no defense to differentiate it from generics, investors are uncertain of how the company will be able to cope.

Click to enlarge - AMAG Chart

Following the news, AMAG's 7.875%/23 bond saw its trading bid drop to a mark of 97.125 at end of day yesterday. The company also has an outstanding TLB L+375, 2021 whose bid remains around 99.750 according to ADI's mark to market pricing service.


Monitor the movement of AMAG and other pharmaceuticals by requesting a free trial of AdvantageData today.


 

Topics: Loans, AMAG, Pharmaceuticals

From the leader in fixed income pricing and data comes market analytics and information you need now.

AdvantageData is your fixed income solution for pricing, analytics, reports, and insight on approximately:

  • 390,000+ U.S. and international corporate bonds
  • Over 5,200 CDS reference entities
  • Over 12,600 syndicated loans
  • 1,500 ETFs
  • Over 100 equity markets worldwide
  • One platform 12 asset classes from debt to CDS to loans to mid-market
  • Used by top buy and sell-side firms worldwide
Why aren't you using AdvantageData?

Subscribe to Email Updates

Recent Posts